Background: Non-small cell lung cancer (NSCLC) predominantly affects older adults; these patients have significant comorbidities, making them unsuitable for chemo-therapy. This study aimed to evaluate the efficacy and safety of immune checkpoint in-hibitor (ICI) along with anlotinib combination therapy as a first-line treatment in older NSCLC patients with programmed death ligand-1(PD-L1) expression<50%. Methods: We conducted a retrospective observational study including 73 patients with ad-vanced NSCLC treated at Nanjing Brain Hospital. All patients were aged 75 years or older and received first-line systemic therapy with a combination of PD-1 inhibitors and anlo-tinib. Clinical data were obtained from electronic medical records and analyzed through Kaplan-Meier estimates and Cox proportional hazards models to assess progression-free survival (PFS), overall survival (OS), and the influence of different variables. Results: The patients had a median age of 80 years. The median PFS was 9.8 months (95% CI: 7.9-11.7), and the median OS was 19.5 months (95% CI: 17.3-21.7). PD-L1 tu-mor proportion score (TPS) <1% (χ2=10.263, P=0.001) and absence of treatment-induced hypertension (χ2=12.804, P<0.001) were identified as independent risk factors for poor PFS. Advanced disease stage (χ2=11.900, P=0.001), PD-L1 TPS <1% (χ2=6.643, P=0.010), and having two or more chronic comorbidities (χ2=9.011, P=0.003) were inde-pendent risk factors for poor OS. Treatment-related hypertension was observed in 25% of patients and was associated with better PFS. Conclusion: ICI-anlotinib combination therapy showed promising efficacy and an ac-ceptable safety profile in older NSCLC patients. Future studies involving larger popula-tions are necessary to validate these findings and determine the potential of PD-L1 levels as a biomarker for treatment stratification.